ASPHF vs PYPD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASPHF is a Hold and PYPD is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ASPHF’s FA Score shows that 0 FA rating(s) are green whilePYPD’s FA Score has 0 green FA rating(s).
- ASPHF’s FA Score: 0 green, 5 red.
- PYPD’s FA Score: 0 green, 5 red.
Price Growth
ASPHF (@Biotechnology) experienced а 0.00% price change this week, while PYPD (@Biotechnology) price change was -12.89% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.91%, and the average quarterly price growth was -1.42%.
Reported Earning Dates
PYPD is expected to report earnings on Feb 05, 2025.
Industries' Descriptions
@Biotechnology (-6.67% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ASPHF | PYPD | ASPHF / PYPD | |
| Capitalization | 1.63B | 19.5M | 8,369% |
| EBITDA | N/A | N/A | - |
| Gain YTD | -16.199 | -34.211 | 47% |
| P/E Ratio | N/A | N/A | - |
| Revenue | N/A | N/A | - |
| Total Cash | N/A | N/A | - |
| Total Debt | N/A | 11.4M | - |
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
ASPHF and
Correlation & Price change
A.I.dvisor indicates that over the last year, ASPHF has been loosely correlated with NERV. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPHF jumps, then NERV could also see price increases.
| Ticker / NAME | Correlation To ASPHF | 1D Price Change % | ||
|---|---|---|---|---|
| ASPHF | 100% | N/A | ||
| NERV - ASPHF | 44% Loosely correlated | +4.57% | ||
| CARA - ASPHF | 35% Loosely correlated | -3.22% | ||
| GPCR - ASPHF | 31% Poorly correlated | +1.55% | ||
| NURPF - ASPHF | 30% Poorly correlated | N/A | ||
| CKPT - ASPHF | 29% Poorly correlated | +9.59% | ||
More | ||||
PYPD and
Correlation & Price change
A.I.dvisor tells us that PYPD and ELEV have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and ELEV's prices will move in lockstep.
| Ticker / NAME | Correlation To PYPD | 1D Price Change % | ||
|---|---|---|---|---|
| PYPD | 100% | +2.88% | ||
| ELEV - PYPD | 30% Poorly correlated | +4.66% | ||
| ASPHF - PYPD | 24% Poorly correlated | N/A | ||
| TENX - PYPD | 23% Poorly correlated | -0.51% | ||
| HOTH - PYPD | 22% Poorly correlated | +1.22% | ||
| VCNX - PYPD | 22% Poorly correlated | -61.37% | ||
More | ||||